Business & Industry

Eli Lilly has expanded its engagement with Insilico Medicine, formalising a new AI drug discovery collaboration valued at up to $2.75 billion, further extending a relationship that began with an AI software licensing agreement in 2023. The latest agreement...

Daiichi Sankyo has formalised a strategic agreement with Tempus AI aimed at accelerating the clinical trajectory and differentiation of an antibody drug conjugate programme within oncology. The collaboration centres on integrating advanced AI capabilities into drug development workflows, with...

The U.S. Food and Drug Administration has initiated a new phase of stakeholder engagement for its national priority voucher pilot program, announcing a public meeting scheduled for June 12, 2026, alongside a Federal Register Notice seeking industry feedback. The...

Merck, known as MSD outside the United States and Canada, confirmed it has signed a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion. The transaction, priced at $53.00 per share in cash, has...

Axplora has reached a key milestone in its ongoing investment strategy, advancing a $60 million programme dedicated to strengthening HPAPI manufacturing capabilities at its Farmabios site in Gropello Cairoli. The latest development involves the construction of a new 4,500...

ICON, a world-leading clinical research organisation, has formalised a definitive partnership agreement with Advarra to introduce a new research-ready trial model designed to reshape how clinical trials are conducted. The collaboration brings together ICON’s global clinical trial solutions with...

Novartis is stepping up its presence in China with a fresh wave of capital deployment, underscoring the country’s growing role in global pharmaceutical strategy. The company confirmed a Novartis China investment exceeding 3.3 billion Chinese yuan (roughly $480 million),...